Marshall Wace North America’s Ultragenyx Pharmaceutical RARE Stock Holding History

Marshall Wace North America’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$18.6M	Buy	206,420 +75,859	+58%	+$6.86M	0.08%	244
2021 Q2	$12.4M	Buy	+130,561	New	+$13.6M	0.05%	339
2021 Q1	–	Sell	-5,160	Closed	-$715K	–	1727
2020 Q4	$715K	Buy	+5,160	New	+$612K	﹤0.01%	1016
2018 Q4	–	Sell	-3,212	Closed	-$245K	–	1603
2018 Q3	$245K	Buy	+3,212	New	+$261K	﹤0.01%	819
2018 Q1	–	Sell	-12,652	Closed	-$587K	–	1655
2017 Q4	$587K	Buy	+12,652	New	+$620K	﹤0.01%	1112

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Marshall Wace North America's RARE Position: Q3 2021 in Review

Marshall Wace North America increased its Ultragenyx Pharmaceutical (RARE) stake by 58% in Q3 2021, buying an estimated $6.86M and bringing the position to 206,420 shares worth $18.6M. The position accounts for 0.08% of the portfolio, ranked #244.

Marshall Wace North America first reported a position in RARE in Q4 2017 and has held it in 5 quarters since. 222 funds tracked by Wall St. Rank hold RARE as of Q3 2021.

Marshall Wace North America held 206,420 shares of Ultragenyx Pharmaceutical worth $18.6M as of Q3 2021.
Marshall Wace North America bought 75,859 Ultragenyx Pharmaceutical shares in Q3 2021, an estimated $6.86M.
Ultragenyx Pharmaceutical made up 0.08% of Marshall Wace North America's portfolio in Q3 2021, its #244 holding.
Marshall Wace North America first reported a position in Ultragenyx Pharmaceutical in Q4 2017 and has held it in 5 quarters since.
222 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.